An Update on Neurodegeneration Panel Discussion at CNS Diseases World Summit

Boston, MA, July 04, 2016 --(PR.com)-- Harry M. Tracy, President of NI Research will be leading a panel discussion, “Update on Neurodegeneration & the State of the Art” at GTCbio’s CNS Diseases World Summit 2016, to be held on September 12th – 15th, 2016 at the Hyatt Boston Harbor in Boston, MA.

Key panelists include:

Eric Karran, Vice President of Foundational Neuroscience, Abbvie
Darryle Schoepp, Vice President and Therapeutic Area Head, Merck
Michael Ehlers, Executive Vice President of Research & Development, Biogen

The 9th CNS Partnering & Deal-making conference, which is a part of our larger CNS Diseases World Summit, seeks to form discussions on all topics from bench to bedside, from changing paradigm in scientific approaches in CNS disorders to partnerships for open innovation to pricing and reimbursement considerations. Colleagues will dialogue and form new relationships in order to forge a path forward into the future of neuroscience.

The CNS Diseases World Summit strives to go beyond just dialogue around research itself, but the partnerships and alliances that need to be formed in order to continue pushing research forward into the future. What are the best models of private/public partnerships? How are patient advocacy groups changing the way we think about funding and research? Colleagues will have the opportunity to build new relationships and move forward together towards the future of neuroscience. Session topics for the CNS Diseases World Summit include:

10th Neurodegenerative Conditions Research & Development
I. Neuroinflammation Across CNS Disorders
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Advances in Genetics and Systems Biology
IV. Biomarkers: Translation from Discovery to Clinical
V. Novel Therapeutics & Approaches in Alzheimer’s Disease
VI. Rare and Orphan CNS Disorders

9th CNS Partnering & Deal-Making
I. CNS: Present and Future
II. Partnering & Licensing in CNS
I. An Update on Neurodegeneration and the State of the Art
II. What Sells Big Pharma in CNS
III. Partnering with Patient Groups to Advance Research
IV. Regulatory Considerations for Orphan Drug Products
V. CNS Perspectives: Venture Capital and Public Markets

For more information, please visit the following website links:
www.gtcbio.com/conferences/cns-diseases-world-summit-overview

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433